Lupin and Lupin Pharmaceuticals, Inc to end litigation on Cefdinir

Lupin Ltd has announced that the Company and Lupin Pharmaceuticals, Inc. ("Lupin") have reached an end to certain District Court litigation proceedings on Cefdinir.

The proceedings emanate from a civil action pending in the United States District Court for the Eastern District of Virginia. captioned Lupin Ltd et al. v. Abbott Laboratories and Astellas Pharma, Inc. et al., Civil Action No. 3:06-CV-400.

By This document, Lupin and Abbott Laboratories and Astellas, Inc. have mutually dismissed various claims against each other without prejudice.

The stock was trading at Rs.688.05, down by Rs.0.20 or 0.03%. The stock hit an intraday high of Rs.695 and low of Rs.672. The total traded quantity was 126848 an at average price of Rs.691.80 resulting in a turnover of Rs.877.53 Lakhs.

Source : Equity Bulls

Keywords